We compared the effects of lipid lowering with rosuvastatin (RSV) monotherapy versus intensified treatment by combining RSV with ezetimibe (EZT) on kidney function in patients undergoing vascular surgery. Patients were randomly assigned to either 10 mg/d RSV (n = 136) or RSV 10 mg/d plus EZT 10 mg/d (RSV/EZT, n = 126). At 12 months, a similar decrease in estimated glomerular filtration rate (eGFR) was noted. Patients who achieved a low-density lipoprotein cholesterol (LDL-C) of <100 mg/dL had less eGFR decrease than those patients having an LDL-C limit of more than 100 mg/dL. There were no significant changes in the urinary total protein to creatinine ratio in either group. Significant microalbuminuria was evident in both the groups. Patients undergoing vascular surgery show deterioration in their renal function during the first year, despite statin therapy. Intensified lipid-lowering therapy by adding EZT does not appear to have any renoprotective effect.
WeltenGMChoncholMSchoutenO. Statin use is associated with early recovery of kidney injury after vascular surgery and improved long-term outcome. Nephrol Dial Transplant. 2008;23(12):3867–3873.
2.
WeltenGMChoncholMHoeksSE. Statin therapy is associated with improved outcomes in vascular surgery patients with renal impairment. Am Heart J. 2007;154(5):954–961.
3.
PatelVILancasterRTMukhopadhyayS. Impact of chronic kidney disease on outcomes after abdominal aortic aneurysm repair. J Vasc Surg. 2012;56(5):1206–1213.
4.
PoldermansDBaxJJBoersmaE. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the task force for preoperative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol. 2010;27(2):92–137.
5.
SchoutenOBoersmaEHoeksSE. Dutch echocardiographic cardiac risk evaluation applying stress echocardiography study group. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med. 2009;361(10):980–989.
6.
SchoutenOKokNFBoersmaE. Effects of statins on renal function after aortic cross clamping during major vascular surgery. Am J Cardiol. 2006;97(9):1383–1385.
7.
MoulakakisKGMatoussevitchVBorgonioAGawendaMBrunkwallJ. Evidence that statins protect renal function during endovascular repair of AAAs. Eur J Vasc Endovasc Surg. 2010;40(5):608–615.
8.
KouvelosGNArnaoutoglouEMMatsagkasMI. Effects of Rosuvastatin With or Without Ezetimibe on Clinical Outcomes in Patients Undergoing Elective Vascular Surgery: Results of a Pilot Study. J Cardiovasc Pharmacol Ther. 2013;18(1):5–12.
9.
SarigianniMKatsikiNMikhailidisDP. Ezetimibe in diabetes: more than cholesterol lowering?Curr Med Res Opin. 2010;26(10):2517–2520.
10.
MikhailidisDPSibbringGCBallantyneCMDaviesGMCatapanoAL. Meta-analysis of the cholesterol- lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin. 2007;23(8):2009–2026.
11.
NakamuraTSatoEFujiwaraN. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol Res. 2010;61(1):58–61.
12.
LeveyASStevensLASchmidCH. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
13.
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1–S266.
14.
GrundySMCleemanJIMerzCN; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239.
15.
AlnaebMEYoussefFMikhailidisDPHamiltonG. Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease. Angiology. 2006;57(1):65–71.
16.
AthyrosVGMikhailidisDPPapageorgiouAA. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57(7):728–734.
17.
Adult Treatment Panel III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421.
18.
MikhailidisDPAthyrosVG. Acute kidney injury: short-term statin therapy for prevention of contrast-induced AKI. Nat Rev Nephrol. 2014;10(1):8–9.
19.
CampeseVMKuEBigazziRBianchiS. Do HMG-CoA reductase inhibitors improve kidney function? the saga continues. J Nephrol. 2011;24(5):550–553.
20.
KalaitzidisRGElisafMS. The role of statins in chronic kidney disease. Am J Nephrol. 2011;34(3):195–202.
21.
KostapanosMSMilionisHJGaziIKostaraCBairaktariETElisafM. Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia. J Clin Pharmacol. 2006;46(11):1337–1343.
22.
GorrizJLMartinez CastelaoA. Proteinuria: detection and role in native renal disease progression. Transplant Rev (Orlando)2012;26(1):3–13.
23.
BrantsmaAHBakkerSJde ZeeuwDde JongPEGansevoortRT, PREVEND Study Group. Extended prognostic value of urinary albumin excretion for cardiovascular events. J Am Soc Nephrol. 2008;19(9):1785–1791.
24.
RossingPHommelESmidtUMParvingHH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia. 1994;37(5):511–516.
25.
EijkelkampWBZhangZRemuzziG. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007;18(5):1540–1546.
26.
ShepherdJKasteleinJJBittnerV; Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2(6):1131–1139.
27.
MigdalisIEfthimiadisAPappasSAlexopoulosDVlasserouFMikhailidisDP. Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Curr Med Res Opin. 2009;25(10):2571–2576.
28.
GaziIFDaskalopoulouSSNairDRMikhailidisDP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin. 2007;23(9):2183–2192.
29.
NakamuraTSatoEFujiwaraN. Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res. 2009;60(6):525–528.
